Literature DB >> 437433

Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat.

A J Wood, J P Villeneuve, R A Branch, L W Rogers, D G Shand.   

Abstract

The elimination of propranolol by perfused livers of rats made cirrhotic by chronic carbon tetrachloride inhalation during phenobarbital treatment has been compared with control animals receiving only phenobarbital. Cirrhosis reduced propranolol clearance at a constant flow of 20 ml/min from 1.43 +/- 0.08 to 1.12 +/- 0.08 ml/min/g liver (P less than 0.025). In addition, an increase in intrahepatic shunting of 15-micron microspheres from 0.41 +/- 0.01 to 9.4 +/- 4.1% was found in cirrhotic livers (P less than 0.05). Finally, in cirrhotic livers, reducing blood flow did not produce the normal rise in hepatic extraction ratio, which actually fell from 0.873 +/- 0.021 at 20 ml/min to 0.836 +/- 0.025 at 15 ml/min and 0.823 +/- 0.026 at 10 ml/min. At each flow the observed extraction was significantly lower than that predicted to result from a reduced enzyme activity alone, consistent with the development of functionally significant intrahepatic shunts. An operational model is proposed that explains impaired drug metabolism in cirrhosis on the basis of the development of intrahepatic shunts which perfuse nonfunctioning tissue, while the remaining blood flow is exposed to a reduced mass of hepatocytes with an apparently normal amount of drug metabolizing enzyme (the intact hepatocyte theory).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 437433

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  20 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance.

Authors:  David G Le Couteur; Robin Fraser; Sarah Hilmer; Laurent P Rivory; Allan J McLean
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

4.  Can intrahepatic shunting be measured?

Authors:  S Keiding
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

5.  A new rat model of portal hypertension induced by intraportal injection of microspheres.

Authors:  Xiang-Nong Li; IS Benjamin; B Alexander
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

6.  Liver metabolic zonation and hepatic microcirculation in carbon tetrachloride-induced experimental cirrhosis.

Authors:  E Gaudio; P Onori; A Franchitto; R Sferra; O Riggio
Journal:  Dig Dis Sci       Date:  1997-01       Impact factor: 3.199

7.  Functional hepatic imaging with receptor-binding radiopharmaceutical: clinical potential as a measure of functioning hepatocyte mass.

Authors:  M Kudo; A Todo; K Ikekubo; M Hino; Y Yonekura; K Yamamoto; K Torizuka
Journal:  Gastroenterol Jpn       Date:  1991-12

8.  Hepatic microcirculation in the perfused cirrhotic rat liver.

Authors:  F Varin; P M Huet
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

9.  Location and function of intrahepatic shunts in anaesthetised rats.

Authors:  X Li; I S Benjamin; R Naftalin; B Alexander
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

10.  Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver.

Authors:  J Reichen; M Le
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.